Biocon Limited announced the successful completion of its buyback of commercial papers, fulfilling its payment obligations. The buyback adheres to SEBI guidelines and has been executed with the consent of the holders. The total buyback amount includes Rs. 1,800 Crores for one ISIN and Rs. 200 Crores for another. The company confirms compliance with all applicable regulations and listing conditions.
Commercial Paper Buyback Completed
Biocon Limited has successfully completed the buyback of its commercial papers (CPs) as of January 30, 2026, fulfilling all related payment obligations. This action complies with SEBI Master Circular guidelines. The buyback was conducted with the consent of the commercial paper holders.
Details of the Buyback
The company bought back two tranches of commercial papers:
- ISIN INE376G14040: Amounting to Rs. 1,800 Crores
- ISIN INE376G14057: Amounting to Rs. 200 Crores
Compliance and Assurances
Biocon confirms that the CPs were issued for the purposes disclosed, and the proceeds were utilized accordingly. The company adheres to all listing conditions and the terms of the offer document. The asset classification of fund-based facilities from banks/financial institutions remains classified as “Standard.” There has been no material change in the company’s financial status adversely affecting the credit rating of the CPs.
Funds Utilization
The commercial papers were initially issued for the following purposes:
- Acquisition of equity shares in subsidiary (for ISIN INE376G14040)
- Redemption of debentures issued by company and acquisition of debentures issued by subsidiary (for ISIN INE376G14057)
Source: BSE
